Synthesis of substituted 3,4-diphenyl-1H-pyrazole-1-carboxylate as potential anti-Alzheimer’s agents and the process of their preparation

IN606968BActive Publication Date: 2026-10-26PRASHANT R MURUMKAR +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202621016617
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2026-02-14
Publication Date
2026-10-26
Estimated Expiration
2046-02-14

AI Technical Summary

Technical Problem

Current treatments for Alzheimer's disease do not halt its progression, and there is a need for new therapies targeting the underlying disease processes, while existing synthesis methods for compounds with MAO-B inhibitory activity involve hazardous hydrazine hydrate.

Method used

A process for synthesizing ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate using thiosemicarbazide and ethyl chloroformate in the presence of glacial acetic acid, avoiding hazardous reagents and providing a less hazardous, industrially feasible method.

Benefits of technology

The synthesized compound demonstrates significant MAO-B inhibitory activity, potentially delaying Alzheimer's disease progression, and offers an environmentally friendly and efficient synthesis process.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

ABSTRACT Synthesis of substituted 3,4-diphenyl-1H-pyrazole-1-carboxylate as potential anti-Alzheimer’s agents and the process of their preparation The present invention relates to a substituted 3,4-diphenyl-1H-pyrazole-1-carboxylate as potential anti-Alzheimer’s agents and the process of their preparation. The present invention specifically relates to ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate compound and process for its preparation.
Need to check novelty before this filing date? Find Prior Art

Description

FILED OF THE INVENTION The present invention relates to a substituted 3,4-diphenyl-1H-pyrazole-1-carboxylate as potential anti-Alzheimer's agents and process of their preparation. The present invention specifically relates to ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate compound and process for its preparation.BACKGROUND OF THE INVENTIONAlzheimer's disease (AD) is a severe neurodegenerative disorder linked to aging, characterized by a significant decline in memory and cognitive abilities. Initially, patients experience memory loss, which progresses to difficulties with language, confusion, mood swings, lack of motivation, and eventually behavioral problems. Over time, brain function deteriorates, leading to a decrease in neurons and, ultimately, death. The rate at which the disease progresses can vary, but on average, individuals may live 3 to 9 years after diagnosis.Currently, there are four main medications approved by the US-FDA to address cognitive symptoms associated with AD: three acetylcholinesterase inhibitors such as galantamine, rivastigmine, and donepezil whereas, one NMDA receptor blocker is memantine. The cholinergic inhibitor tacrine was withdrawn from the market in 2013 due to liver toxicity concerns. While these treatments can provide some temporary relief for cognitive deficits, they do not halt the progression of Alzheimer's or offer a cure. This highlights the need for continued research and development of new therapies that target the underlying disease processes and potentially delay its onset.The causes of AD are complex and not fully understood, involving a mix of genetic, environmental, and internal factors. Several key theories attempt to explain the disease's development, including the cholinergic hypothesis, oxidative stress, the tau hypothesis, the amyloid-cascade hypothesis, and metal ion imbalance. Recent research has also identified new potential targets for treatment, like GSK-3β, PDEs, and monoamine oxidase (MAO).Indian patent application no. 202421095741 discloses compound of Formula I (shown below) having MAO-B inhibitory activity. Another Indian patent application no. 202521005283 discloses compound of Formula I (shown below) having MAO-B inhibitory activity. Both the above patent applications disclose phenyl 3,4-diphenyl-1H-pyrazole-1-carboxylate as an intermediate for the synthesis of compounds having MAO-B inhibitory activity. The synthesis of this compound involves toxic / hazardous hydrazine hydrate.However, there is a need for further compounds having MAO-B inhibitory activity and also environment friendly, less hazardous, industrially feasible process for the preparation of these compounds.SUMMARY OF THE INVENTIONThe present invention relates to a process for preparation of compound of formula I Icomprising steps of a) reacting compound of formula II IIwith thiosemicarbazide of formula III IIIin presence of glacial acetic acid to obtain compound of formula IV, and IVb) reacting compound of formula IV with ethyl chloroformate in a suitable solvent to obtain compound of formula I.The present invention also relates to a compound ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate having following formula I (I).DETAILED DESCRIPTION OF THE INVENTIONIn one embodiment, the present invention relates to a compound ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate having following formula I (I).In another embodiment, the present invention relates to a process for preparation of compound of formula I Icomprising steps of a) reacting compound of formula II IIwith thiosemicarbazide of formula III IIIin presence of glacial acetic acid to obtain compound of formula IV, IV andb) reacting compound of formula IV with ethyl chloroformate in a suitable solvent to obtain compound of formula I.The reaction of step a) can be performed at a temperature of 70 to 140 °C, preferably at the 100 to 120 °C.The quantity of thiosemicarbazide in step a) can be in range of 2 to 4 mol per mole of compound of formula II.The reaction of step b) can be performed at a temperature of 0 to 10 °C, preferably at the 0 to 5 °C.The quantity of ethyl chloroformate in step b) can be in range of 1 to 1.5 mol per mol of compound of formula IV.The solvent in step b) can be selected from dichloromethane, chloroform, toluene, tetrahydrofuran, dioxane, dimethylformamide or dimethylsulfoxide preferably dichloromethane.In another embodiment, the present invention relates to a method of treating a subject suffering from Alzheimer's disease comprising administering a therapeutically effective dose of a compound ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate to the said subject.EXAMPLESThe following examples illustrate specific embodiments; however, the full scope of the disclosure is not limited to the examples described below.Example 1Preparation of 3,4-diphenyl-1H-pyrazole (IV)(E)-3-(dimethylamino)-1,2-bis(phenyl)prop-2-en-1-one (II) (1 g, 3.97 mmol) was taken in a clean, dry RBF and glacial acetic acid (20 ml) and thiosemicarbazide (III) (0.72 g, 7.9 mmol) were added and the reaction mixture was allowed to reflux for 5 hrs. The reaction mixture was poured into ice cold water and sodium bicarbonate was added to neutralize the pH. The precipitate was filtered to obtain title compound (IV).White solid; yield: 0.80 g, 90.90 %; Mp: 126-128 °C (Lit (IN202521005283A): 126-128 °C); TLC: Rf : 0.37 (n-Hexane: ethyl acetate; 7:3); IR (cm-1): 3140, 2838, 1602, 758; 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.47 (dd, J = 6.7, 3.0 Hz, 2H), 7.35 - 7.32 (m, 3H), 7.31 (d, J = 4.4 Hz, 3H), 7.26 (d, J = 6.8 Hz, 2H); MS (ESI+) m / z: 220.9 (M)+.Example 2Preparation of ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (I) 3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry dichloromethane (DCM) (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of ethyl chloroformate (0.56 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound (I). Yield 75%; Off white solid; Mp: 101-103 °C; Rf : 0.34 (CHCl3: CH3OH (18:02); IR (cm-1): 3079, 2853, 1734; 1H-NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.53 (d, J = 5.8 Hz, 2H), 7.32 (d, J = 8.6 Hz, 6H), 7.29 - 7.26 (m, 2H), 4.57 (q, J = 7.1 Hz, 2H), 1.49 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 154.12, 149.45, 131.72, 131.43, 130.02, 128.75, 128.72, 128.66, 128.54, 128.25, 127.56, 125.77, 124.46, 64.70, 14.31; HRMS (m / z): 293.1294 (M+H)+.Comparative example 1Preparation of phenyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of phenyl chloroformate (0.74 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound.Yield 76%. Pale yellow solid; Mp: 138-140 °C; Rf : 0.38 (n-hexane: Ethyl acetate (18:02); IR (cm-1): 3105, 2978, 1780; 1H-NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.58 (dd, J = 7.9, 1.8 Hz, 2H), 7.47 (t, J = 8.0 Hz, 2H), 7.36 -7.31 (m, 10H), 7.29 -7.26 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 154.90, 150.34, 148.11, 131.47, 131.16, 130.43, 129.68, 128.95, 128.77, 128.70, 128.61, 128.34, 127.77, 126.71, 125.22, 121.28; HRMS (m / z): 341.1305 (M+H)+.Comparative example 2Preparation of isobutyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of isobutyl chloroformate (0.76 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound. Yield 78%; Pale yellow solid; Mp: 106-108 °C ; Rf : 0.36 (CHCl3: CH3OH (18:02); IR (cm-1): 3059,2874, 1744; 1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.35 - 7.31 (m, 6H), 7.29 (d, J = 3.0 Hz, 2H), 4.29 (d, J = 6.9 Hz, 2H), 2.19 (m, 1H), 1.05 (d, J = 6.8 Hz, 6H).; 13C NMR (101 MHz, CDCl3) δ 154.00, 149.40, 131.73, 131.47, 129.89, 128.71, 128.69, 128.52, 128.21, 127.74, 127.56, 124.44, 74.24, 27.80, 18.98, 18.92; HRMS (m / z): 321.1642 (M+H)+.Comparative example 3Preparation of methyl 3,4-diphenyl-1H-pyrazole-1-carboxylate 3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of methyl chloroformate (0.45 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound.Yield 74%; Off white solid; Mp: 103-105 °C; Rf : 0.32 (CHCl3:CH3OH (18:02); IR (cm-1): 3157, 2853, 1750; 1H-NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.54 - 7.50 (m, 2H), 7.33 (dd, J = 7.6, 2.1 Hz, 6H), 7.28 - 7.26 (m, 2H), 4.12 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 154.28, 150.00, 131.57, 131.27, 130.05, 128.78, 128.70, 128.63, 128.54, 128.26, 127.61, 124.61, 55.01. Comparative example 4Preparation of pentyl 3,4-diphenyl-1H-pyrazole-1-carboxylate 3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of pentyl chloroformate (0.84 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound. Yield 85%; Pale yellow solid; Mp: 104-106 °C; Rf : 0.38(CHCl3: CH3OH (18:02). IR (cm-1): 2951, 2853, 1735; 1H-NMR (400 MHz, CDCl3) δ 8.22 (s, 1H), 7.53 (dd, J = 7.8, 1.8 Hz, 2H), 7.34 - 7.31 (m, 6H), 7.29 - 7.27 (m, 2H), 4.50 (t, J = 6.9 Hz, 2H), 1.86 (p, J = 6.9 Hz, 2H), 1.45 - 1.38 (m, 4H), 0.94 (t, J = 7.1 Hz, 3H; 13C-NMR (101 MHz, CDCl3) δ 154.06, 149.49, 131.73, 131.47, 129.97, 128.74, 128.71, 128.68, 128.54, 128.24, 127.56, 124.44, 68.71, 28.28, 27.76, 22.26, 13.89; HRMS (m / z): 335.1771 (M+H)+.Comparative example 5Preparation of hexyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of hexyl chloroformate (0.95 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound. Yield 82%; White solid; Mp: 60-62 °C; Rf : 0.4 (CHCl3: CH3OH (18:02); IR (cm-1): 3058, 2921, 1734; 1H NMR (400 MHz, CDCl3) δ 8.22 (s, 1H), 7.53 (d, J = 5.9 Hz, 2H), 7.32 (dd, J = 5.8, 1.9 Hz, 6H), 7.29 - 7.26 (m, 2H), 4.49 (t, J = 6.9 Hz, 2H), 1.85 (p, J = 7.0 Hz, 2H), 1.44 (q, J = 6.6 Hz, 2H), 1.37 - 1.31 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 154.01, 149.44, 131.69, 131.42, 129.93, 128.70, 128.67, 128.64, 128.50, 128.20, 127.52, 124.40, 68.68, 31.30, 28.50, 25.29, 22.44, 13.93; HRMS (m / z): 349.1933 (M+H)+.Comparative example 6Preparation of 1-chloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of 1-chloroethyl chloroformate (0.63 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound.Yield 90%; Pale yellow solid; Mp: 70-72 °C ; Rf : 0.34 (CHCl3:CH3OH (18:02); IR (cm-1): 2985, 2888, 1734; 1H-NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.58 (d, J = 7.9 Hz, 2H), 7.43 - 7.34 (m, 6H), 7.30 (d, J = 3.8 Hz, 2H), 3.15 (s, 4H); 13C-NMR (101 MHz, CDCl3) δ 130.28, 130.04, 128.97, 128.87, 128.66, 128.61, 128.36, 127.98, 127.16, 45.98, 8.72.Comparative example 7 Preparation of benzyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of benzyl chloroformate (0.83 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound.Yield 81%; Pale yellow solid; Mp: 132-134 °C; Rf : 0.34 (CHCl3:CH3OH (18:02); IR (cm-1): 3061, 2926, 1743; 1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.55 (d, J = 6.4 Hz, 1H), 7.47 - 7.44 (m, 2H), 7.36 - 7.33 (m, 4H), 7.31 (d, J = 4.5 Hz, 4H), 4.86 (s, 2H); 13C-NMR (101 MHz, CDCl3) δ 154.29, 149.38, 134.47, 131.65, 131.37, 130.07, 128.93, 128.84, 128.76, 128.72, 128.68, 128.55, 128.34, 128.26, 127.61, 124.63, 69.90.Comparative example 8Preparation of 2,2,2-trichloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate3,4-Diphenyl-1H-pyrazole (IV) (1 g, 4.5 mmol) was taken in a clean dry RBF and dry DCM (15 ml) was added and stirred in ice bath till temperature attained 0-5 °C. Triethylamine (1.87 ml, 13.4 mmol) was added in the reaction mixture followed by slow addition of 2,2,2-trichloroethyl chloroformate (0.80 ml, 5.8 mmol). The reaction mixture was stirred for 1 hr and TLC was monitored. The reaction was poured into ice cold water and extracted with CHCl3 (25ml x 3). The organic layer was combined, dried over Na2SO4 and evaporated to obtain the title compound. Yield 75%; Pale yellow solid; Mp: 128-130 °C; Rf : 0.36 (CHCl3: CH3OH (18:02); IR (cm-1): 3157, 2926, 1772; 1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.55 (d, J = 6.4 Hz, 1H), 7.47 - 7.44 (m, 2H), 7.36 - 7.33 (m, 4H), 7.31 (d, J = 4.5 Hz, 4H), 4.86 (s, 2H); 13C-NMR (101 MHz, CDCl3) δ 155.26, 153.12, 133.03, 131.24, 128.78, 128.73, 128.62, 128.49, 128.37, 128.16, 126.56, 119.88, 93.89, 76.16; HRMS (m / z): 395.0087 (M+H)+. Example 3MAO-B inhibition assayMAO-B activity [Hall DW, Logan BW, Parsons GH. Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline)-I: Substrate specificity in various mammolalian species. Biochemical pharmacology. 1969 Jun 1;18(6):1447-54.][ Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Analytical biochemistry. 1997 Nov 15;253(2):162-8.] in STHdhQ7 / Q7 cells was measured using the Amplex Red Monoamine Oxidase Assay Kit (Invitrogen, USA) with modifications to the manufacturer's protocol. Cells were lysed in M-PER Mammolalian Protein Extraction Reagent (Thermo Fisher Scientific) supplemented with a 1x protease inhibitor cocktail (Sigma-Aldrich). Following a 30-minute incubation on ice, the lysate was centrifuged at 14,000 rpm for 15 minutes at 4°C. The supernatant was collected for subsequent analysis. Protein concentration was determined by the Bradford assay (Bio-Rad Protein Assay Dye Reagent Concentrate, Bio-Rad), and 4 μg of protein was used per well in the MAO-B activity assay. Benzylamine hydrochloride for MAO-B enzyme was used as a substrate. Sodium phosphate buffer (0.05 M, pH 7.4) was used for all the enzyme reactions and dilutions. The final reaction volume was 200 μl, containing the substrate, 10 μM test inhibitor, and DMSO as the co-solvent. The effects of test compounds on MAO-B activity were evaluated by measuring H2O2 production from benzylamine using the Amplex Red assay kit. Briefly, 0.1 ml of sodium phosphate buffer (0.05 M, pH 7.4) containing 10 μM test compound and 4 μg of protein (STHdhQ7 / Q7 cell lysate) were incubated for 1 hour at 37°C in a 96-well plate to ensure maximal binding and reaction equilibrium. After this incubation period, the reaction was initiated by adding 200 μM Amplex Red reagent, 1 U / mL horseradish peroxidase, and 1 mmol benzylamine hydrochloride (final concentrations) for 1 hour at RT. Fluorescence intensity (excitation 560 nm, emission 590 nm), proportional to H2O2 production and, consequently, of resorufin, was measured using a Synergy HTX Multi-Mode Microplate Reader (BioTek Instruments).Control experiments were carried out simultaneously by replacing the test drugs (new compounds and reference inhibitors) with appropriate dilutions of the vehicles. Background fluorescence was subtracted, and data were normalized to wells containing no inhibitor (0 μM) to calculate %inhibition. Based on these results, three most potent compounds [Ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (I) (Example 2), Phenyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 1) and 2,2,2-Trichloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 8)] were selected for IC50 determination. IC50 values were calculated using the curvatures of log (inhibitor) vs normalized response with a variable slope in GraphPad Prism: version 6. Initial compound concentrations ranging from 0 to 10 μM were used for IC50 calculations.Percentage of inhibition of MAO-B activities of the compounds are given in Table 1 and IC50 values are given in Table 2.Table 1: % MAO-B inhibition of compoundsCompound % inhibitionEthyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (I) (Example 2) 100Phenyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 1) 98Isobutyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 2) 93Methyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 3) 90Pentyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 4) 86Hexyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 5) 931-Chloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 6) 86Benzyl 3,4-diphenyl-1H-pyrazole-1-carboxylate(Comparative example 7) 922,2,2-Trichloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 8) 100Pargyline (Standard) 100*mean of n=3Table 2: MAO-B inhibitory activity (IC50) of compoundsCompounds IC50 (nM)Ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (I) (Example 2) 5.14Phenyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 1) 41.52,2,2-Trichloroethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate (Comparative example 8) 27.0

Claims

1. A compound ethyl 3,4-diphenyl-1H-pyrazole-1-carboxylate having following formula I (I).

2. A process for preparation of compound of formula I I comprising steps of a) reacting compound of formula II II with thiosemicarbazide of formula III III in presence of glacial acetic acid to obtain compound of formula IV, IV and b) reacting compound of formula IV with ethyl chloroformate in a suitable solvent to obtain compound of formula I.

3. The process as claimed in claim 2 wherein the reaction of step a) is performed at a temperature of 70 to 140 °C.

4. The process as claimed in claim 2 wherein the quantity of thiosemicarbazide in step a) is in range of 2 to 4 mol per mol of compound of formula II.

5. The process as claimed in claim 2 wherein the reaction of step b) is performed at a temperature of 0 to 10 °C.

6. The process as claimed in claim 2 wherein the quantity of ethyl chloroformate in step b) is in range of 1 to 1.5 mol per mol of compound of formula IV.

7. The process as claimed in claim 2 wherein the solvent in step b) is selected from dichloromethane, chloroform, toluene, tetrahydrofuran, dioxane dimethylformamide or dimethylsulfoxide.